Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance.
about
Recent advances in the field of anti-cancer immunotherapyPractical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodiesFactors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study.Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomes.The clinical development of obinutuzumab for the treatment of follicular lymphoma.A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphomaFailure of oral atorvastatin to modulate a murine model of systemic lupus erythematosus.Non-infectious pulmonary toxicity of rituximab: a systematic review.Monoclonal antibodies in the treatment of malignancy: basic concepts and recent developments.Monoclonal antibody therapy for lymphoma: an update.Role of rituximab in first-line treatment of chronic lymphocytic leukemia.Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol.Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemiaMolecular biological design of novel antineoplastic therapies.Rituximab for the treatment of diffuse large B-cell lymphomas.Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma.Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trialInfiltrative lung diseases: complications of novel antineoplastic agents in patients with hematological malignancies.Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia.Neglected respiratory toxicity caused by cancer therapy.A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.A review of tumour lysis syndrome with targeted therapies and the role of rasburicase.Bone marrow involvement is predictive of infusion-related reaction during rituximab administration in patients with B cell lymphoma.Treatment strategy for reducing the risk of rituximab-induced cytokine release syndrome in patients with intravascular large B-cell lymphoma: a case report and review of the literature.Obinutuzumab for the treatment of indolent lymphomaIncidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience.Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties.A clinical prediction model for infusion-related reactions to rituximab in patients with B cell lymphomas.Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.Rituximab and cytokine release syndrome.Rituximab-induced coronary vasospasm.Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions.The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia.Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, mulInfusion Related Hypersensitivity Reactions with Bio-similar Anti CD-20 Monoclonal Antibody Rituximab in Indian Patients: A Retrospective Study.Tolerance, loss of tolerance and regaining tolerance to self by immune-mediated events.Posttransplant Lymphoproliferative Disorder after Cardiac Transplantation in Children: Life Threatening Complications Associated with Chemotherapy Combined with Rituximab
P2860
Q26775602-906D2A52-57BD-454B-8F84-F69BAE698BC8Q27690917-18B5D003-0755-4328-A4F4-EB030DB36ACFQ33343262-BA79DB63-6CF5-4661-9665-E561C43B736AQ33414468-C643D365-1F48-4CF4-9A5B-F6F7D57D0D11Q33565265-089FA2B2-FF56-4FD3-9399-8D8893C05E97Q33905245-5B1AB7D8-E4C9-41C0-B1FB-6F716CE45748Q34084153-CBE6D597-A3FD-4504-BC60-4F68E4510A4DQ34096300-9ECB4969-BF14-45E6-85FA-CDC87622CF55Q34478304-2C4445CD-FA7D-4EDB-81BC-F0720CC29602Q34552428-4630D2C8-8CEF-4941-AF3C-5E7611E2C016Q34574147-F28DF169-CDFC-4CBF-AE32-82EF90BC6C3CQ35182162-E3D7DAD1-712C-435B-B019-F98E3EF53818Q35615823-E6E33127-20E6-4DF2-82AE-D3D65B19CC30Q35790781-698F4A8C-BBC9-49DD-949A-59A03560480DQ36573823-87E3FB2E-78BC-468F-B94B-7677E2183803Q37040836-A66DA83D-D752-4DF8-B5FC-E167CED7365AQ37144563-AB1CBD36-9E79-463D-A371-7CC84708DA14Q37190474-60BD0B33-354F-4476-BCF1-B3897B1818D6Q37334965-C5014F59-A9C7-4DCD-8B07-936A41841985Q37429804-F16668E1-1FC4-479F-A567-553DC0CC47EAQ37672472-5EBAE538-BB03-4234-8308-0AA4D848A24AQ37866341-472A3D42-F993-4ED0-87B6-0E2A544372A3Q38056669-73202864-6D78-4337-9CA5-234FB1AE6A41Q38174643-776167C3-051C-4CDA-980D-765CE38AFD22Q38818380-F8AA83FD-5E32-4DB0-9E17-EFD28262C780Q38968266-FA8F6D82-4B9C-4219-A276-68653DB914D8Q39192585-E4132515-4192-49F4-9358-CC42532B7129Q40070997-D1F60339-288F-4130-A2EF-490248459027Q40329298-4438279D-91F6-457E-82FC-84F9688A19A4Q41859216-F5D15679-F00B-45A3-8693-3273D55E33ACQ42278780-189E2ABD-E47A-47DE-94E0-4385DBC134D2Q42372842-93F05A3E-0A61-4174-9CA7-C41ACD84CF70Q42643278-334113ED-4F12-4019-970A-B2A6DD51EE06Q46801651-74DD9593-E468-460C-80F8-B2C9672DA5FDQ48337788-3F4536BB-D12C-421F-BDB3-F3F2DB36383DQ52603729-E51CF955-5D15-456A-BCD7-0E5B97F3A7EEQ52985913-54ECBE55-75A4-4A52-ACC7-951A3D489299Q58998353-C8FD23C5-6299-4C57-850D-10CF2F2D83DF
P2860
Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance.
description
1999 nî lūn-bûn
@nan
1999 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մարտին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Rituximab therapy in hematolog ...... d rapid blood tumor clearance.
@ast
Rituximab therapy in hematolog ...... d rapid blood tumor clearance.
@en
Rituximab therapy in hematolog ...... d rapid blood tumor clearance.
@nl
type
label
Rituximab therapy in hematolog ...... d rapid blood tumor clearance.
@ast
Rituximab therapy in hematolog ...... d rapid blood tumor clearance.
@en
Rituximab therapy in hematolog ...... d rapid blood tumor clearance.
@nl
prefLabel
Rituximab therapy in hematolog ...... d rapid blood tumor clearance.
@ast
Rituximab therapy in hematolog ...... d rapid blood tumor clearance.
@en
Rituximab therapy in hematolog ...... d rapid blood tumor clearance.
@nl
P2093
P1476
Rituximab therapy in hematolog ...... d rapid blood tumor clearance.
@en
P2093
B P Monahan
J K Waselenko
T J Maneatis
P304
P356
10.1200/JCO.1999.17.3.791
P407
P577
1999-03-01T00:00:00Z